<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549234</url>
  </required_header>
  <id_info>
    <org_study_id>Erector Spinae vs PVB</org_study_id>
    <nct_id>NCT03549234</nct_id>
  </id_info>
  <brief_title>Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery</brief_title>
  <official_title>A Randomized, Subject-Masked, Active-Controlled, Parallel-Arm Clinical Trial Comparing Erector Spinae and Paravertebral Nerve Blocks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following painful surgical procedures of the breast, postoperative analgesia is often&#xD;
      provided with a paravertebral nerve block (PVB). For intense, but shorter-duration acute&#xD;
      pain, a single-injection of local anesthetic is used with a duration of approximately 12&#xD;
      hours. The PVB has several limitations: it can decrease blood pressure, and very rare-but&#xD;
      serious-complications have occurred, including neuraxial injection, neuraxial hematoma, and&#xD;
      pleural puncture. An alternative block has been described: the erector spinae plane block.&#xD;
      The theoretical benefits include ease of administration since it is a plane superficial to&#xD;
      the PVB and therefore easier to identify and target with ultrasound (therefore increasing&#xD;
      success rate); and an increased safety margin: there are few anatomic structures in the&#xD;
      immediate area which could be injured with the needle; and, the target plane is much further&#xD;
      from the intrathecal/epidural space relative to the PVB. Lastly, the plane may be easier to&#xD;
      catheterize for continuous peripheral nerve blocks relative to the relatively-small volume&#xD;
      PVB.&#xD;
&#xD;
      There are therefore multiple theoretical reasons to prefer the erector spinae plane block.&#xD;
      Unfortunately, it remains unknown if the analgesia provided by this new technique is&#xD;
      comparable to that provided with the PVB. The investigators therefore propose to compare&#xD;
      these two techniques with a randomized, subject-masked, active-controlled, parallel-arm,&#xD;
      human subjects clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigation will be a randomized, subject-masked, active-controlled parallel-arm,&#xD;
      human subjects clinical trial. Of note, the investigators will be using standard-of-care&#xD;
      local anesthetic under an FDA-approved purpose and do not plan to research a possible change&#xD;
      of indication or use of these medications as part of this research project. The treatments in&#xD;
      both groups are currently used at the study institution and there is true clinical equipoise&#xD;
      at this time. The only difference in treatment between subjects who enroll versus those not&#xD;
      enrolled in this study will be those who enroll will have the decision between which anatomic&#xD;
      block location determined randomly, as opposed to the physician simply choosing him/herself.&#xD;
&#xD;
      Enrollment. Consenting adults undergoing breast surgery with a planned single-injection&#xD;
      regional analgesic will be offered enrollment. Patients undergoing breast surgery with a&#xD;
      planned perineural catheter regional analgesic will be excluded. Study inclusion will be&#xD;
      proposed to eligible patients prior to surgery. If a patient desires study participation,&#xD;
      written, informed consent will be obtained using a current University of California San Diego&#xD;
      (UCSD) Institutional Review Board (IRB)-approved Informed Consent Form (ICF). Selection for&#xD;
      inclusion will not be based on gender, race, or socioeconomic status. The study population of&#xD;
      interest includes men and women of all races and socioeconomic status. Inclusion and&#xD;
      exclusion criteria are listed in another section.&#xD;
&#xD;
      Preoperative Procedures. Following written, informed consent, the investigators will collect&#xD;
      baseline anthropomorphic information (e.g., age, sex, height, and weight). All subjects will&#xD;
      have a peripheral intravenous (IV) catheter inserted, standard noninvasive monitors applied,&#xD;
      supplemental oxygen administered via a nasal cannula or face mask, and placed in the sitting&#xD;
      position. Midazolam and fentanyl (IV) will be titrated for patient comfort, while ensuring&#xD;
      that patients remain responsive to verbal cues. Both possible block locations will be viewed&#xD;
      with ultrasound. If one or both of the locations is unacceptable for block placement in the&#xD;
      clinician's opinion, the subject will not be randomized and will not proceed further with the&#xD;
      study.&#xD;
&#xD;
      Subjects will then be randomized using a computer-generated list and opaque, sealed envelopes&#xD;
      to one of two treatment groups: (blocks of 4, stratified for unilateral vs. bilateral&#xD;
      surgery): (1) erector spinae plane or (2) paravertebral block. All blocks will be placed by a&#xD;
      regional anesthesia fellow or resident under the direct supervision and guidance of a&#xD;
      regional anesthesia attending (or by the attending him/herself).&#xD;
&#xD;
      The area of needle insertion will be cleaned with chlorhexidine gluconate and isopropyl&#xD;
      alcohol. All blocks will be placed using standard UCSD ultrasound-guided techniques.&#xD;
&#xD;
      Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle&#xD;
      into the target plane. For erector spinae plane blocks, this will be at the T3 level for&#xD;
      surgery involving the axilla and the T4 level for surgery not involving the axilla (20 mL of&#xD;
      local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral&#xD;
      surgery). For PVBs without axillary work, this will be at the T3 and T5 levels. For PVBs with&#xD;
      axillary work, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local&#xD;
      anesthetic will be injected per level. For bilateral PVBs, 8 mL of local anesthetic will be&#xD;
      injected per level.&#xD;
&#xD;
      Single-injection blocks will be considered successful if, within 30 minutes, the subject&#xD;
      experiences decreased sensation to cold temperature with an alcohol pad over the approximate&#xD;
      level of the ipsilateral 4th thoracic dermatome. Misplaced blocks will be replaced&#xD;
      successfully, or the patient excluded from further study participation. For subjects&#xD;
      undergoing bilateral surgical procedures, a block using the same protocol will be&#xD;
      administered on the contralateral side.&#xD;
&#xD;
      Intraoperatively, all subjects will receive a general anesthetic using inhaled and&#xD;
      intravenous anesthetic and oxygen. Intravenous fentanyl will be administered for&#xD;
      cardiovascular responsiveness to noxious stimuli at the discretion of the anesthesia&#xD;
      provider.&#xD;
&#xD;
      Postop: Subjects will be discharged with a prescription for oxycodone 5 mg tablets for&#xD;
      supplementary analgesia and instructed to record the time at which subjects take their first&#xD;
      opioid tablet as well as the time at which subjects believe the block starts to wear off.&#xD;
&#xD;
      Outcome measurements (end points). Pain scores will be recorded using the Numeric Rating&#xD;
      Scale (NRS). Within the recovery room, pain scores, opioid requirements, and antiemetic&#xD;
      administration will be recorded by nursing staff masked to treatment group. The morning&#xD;
      following surgery, all subjects will be contacted by phone or in person [if hospitalized] to&#xD;
      record lowest, average, highest, and current pain scores; sleep disturbances, and nausea&#xD;
      using a 0-10 Likert scale (0 = no nausea; 10 = vomiting). For outpatients, opioid&#xD;
      requirements will be recorded while inpatients will have opioid requirements extracted from&#xD;
      the electronic medical record. In addition, the investigators will extract antiemetic use&#xD;
      from the electronic record. The investigators will collect the times at which subjects felt&#xD;
      their block resolve and subjects consumed their first opioid analgesic pills following&#xD;
      recovery room discharge.&#xD;
&#xD;
      Hypothesis 1: Following breast surgery, analgesia will be non-inferior in the recovery room&#xD;
      with an erector spinae plane block compared with a paravertebral block as measured with the&#xD;
      Numeric Rating Scale.&#xD;
&#xD;
      Hypothesis 2: For breast surgery, opioid consumption will be non-inferior in the operating&#xD;
      and recovery rooms with an erector spinae plane block compared with a paravertebral block&#xD;
      (primary: cumulative intravenous morphine equivalents).&#xD;
&#xD;
      Primary end point: In order to claim that erector spinae plane blocks are non-inferior to&#xD;
      paravertebral blocks, both Hypotheses 1 and 2 must be at least non-inferior.&#xD;
&#xD;
      Statistical methods. Descriptive statistics will be provided by arm and in aggregate.&#xD;
      Baseline characteristics of arms will be compared using the Wilcoxon-Mann-Whitney and&#xD;
      Fisher's Exact tests. Key characteristics that are significantly different (p&lt;0.05) will be&#xD;
      included as covariates in the analysis models.&#xD;
&#xD;
      Primary aim. The investigators will test the noninferiority of the erector spinae nerve block&#xD;
      compared to the paravertebral nerve block. The 95% confidence interval (CI) associated with&#xD;
      the Wilcoxon-Mann-Whitney test will be derived for the group difference (paravertebral minus&#xD;
      erector spinae) in median pain scores within the recovery room. If the lower limit of the 95%&#xD;
      CI is greater than -1.25, the investigators will conclude noninferiority. If there are&#xD;
      significant differences between the groups in any key characteristics, these characteristics&#xD;
      will be included as covariates in a linear model. The same noninferiority margin (-1.25) will&#xD;
      be applied to the 95% CI for the covariate adjusted group difference in mean pain derived&#xD;
      from the linear model.&#xD;
&#xD;
      The noninferiority of the erector spinae nerve block with regard to total opioid consumption&#xD;
      within the operating and recovery rooms will be tested in the same manner as pain, i.e.&#xD;
      comparing the limits of a 95% CI associated with the Wilcoxon-Mann-Whitney test to a&#xD;
      predefined noninferiority margin (in this case 2 mg). Covariate adjusted linear models will&#xD;
      again be applied in the event that key characteristics are significantly different between&#xD;
      the groups.&#xD;
&#xD;
      Sample size justification. Power for the Wilcoxon-Mann-Whitney derived noninferiority testing&#xD;
      is based on 10,000 simulated trials. The investigators simulated pain scores from a discrete&#xD;
      distribution with median (interquartile range) 3 (2-5) [Kairaluoma, 2004]. Between the&#xD;
      quartiles, the probability of each score was assumed constant. The distribution for each&#xD;
      group was assumed to be the same. The sample size of n=50 per group provides 82% power to&#xD;
      detect noninferiority in pain with a margin of 1.25. Similarly, opioid consumption was&#xD;
      assumed to follow a truncated normal distribution with mean 2.5 mg and standard deviation 2&#xD;
      mg, and minimum value 0 mg. The sample size of n = 50 per group provides at least 95% power&#xD;
      to detect noninferiority with margin 2 mg. Therefore, the investigators will enroll 50&#xD;
      subjects for each of two treatments with a total enrollment of 100 subjects. To allow for&#xD;
      dropouts, the investigators will request a maximum enrollment of 120 subjects. Noninferiority&#xD;
      in pain is tested first, and if significant, noninferiority in opioid consumption is tested.&#xD;
      Under this hierarchical testing framework, no adjustment in alpha is necessary to control&#xD;
      Type 1 error [Mascha, et al 2012].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Actual">May 8, 2019</completion_date>
  <primary_completion_date type="Actual">May 8, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating Scale Pain Scores</measure>
    <time_frame>1 day (PACU pain scores)</time_frame>
    <description>Range scale minimum 0, maximum 10. Lower pain scores are considered a better outcome, higher pain scores are considered a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OR and PACU Opioid Consumption</measure>
    <time_frame>up to 1 day, in the OR and PACU</time_frame>
    <description>This outcome measure reflects the total amount of opioid administered in the operating room and recovery room perioperatively. Specific time points are not applicable since operating room and recovery room times differ among subjects.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Nausea and Vomiting</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Nausea and vomiting was recorded using a 0-10 Likert scale (0 = no nausea; 10 = vomiting) on postoperative day 1. Higher scores represent a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep Disturbances</measure>
    <time_frame>postoperative day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Block Resolution</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>This was recorded as the time at which a participant subjectively noticed that the nerve block was wearing off and sensation was returning.</description>
  </other_outcome>
  <other_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Number of oxycodone tablets (in mg) taken by the participant after discharge from the recovery room was recorded during follow-up on postoperative day 1.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Breast Surgery</condition>
  <arm_group>
    <arm_group_label>Erector Spinae (single injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paravertebral (single injection)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erector Spinae (single injection)</intervention_name>
    <description>Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
    <arm_group_label>Erector Spinae (single injection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paravertebral (single injection)</intervention_name>
    <description>Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
    <arm_group_label>Paravertebral (single injection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  undergoing unilateral or bilateral breast surgery with at least moderate postoperative&#xD;
             pain anticipated&#xD;
&#xD;
          -  analgesic plan includes a single-injection peripheral nerve block(s)&#xD;
&#xD;
          -  age 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  morbid obesity as defined by a body mass index &gt; 40 (BMI=weight in kg / [height in&#xD;
             meters]2)&#xD;
&#xD;
          -  renal insufficiency (preoperative creatinine &gt; 1.5 mg/dL)&#xD;
&#xD;
          -  chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use&#xD;
             &gt; 4 weeks)&#xD;
&#xD;
          -  history of opioid abuse&#xD;
&#xD;
          -  any comorbidity which results in moderate or severe functional limitation&#xD;
&#xD;
          -  inability to communicate with the investigators or hospital staff&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  planned regional analgesic with perineural catheter placement&#xD;
&#xD;
          -  incarceration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Ilfeld, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor in Residence</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center (Hillcrest and Thornton)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Naja Z, LÃ¶nnqvist PA. Somatic paravertebral nerve blockade. Incidence of failed block and complications. Anaesthesia. 2001 Dec;56(12):1184-8.</citation>
    <PMID>11736777</PMID>
  </reference>
  <reference>
    <citation>Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451.</citation>
    <PMID>27501016</PMID>
  </reference>
  <reference>
    <citation>Forero M, Rajarathinam M, Adhikary S, Chin KJ. Continuous Erector Spinae Plane Block for Rescue Analgesia in Thoracotomy After Epidural Failure: A Case Report. A A Case Rep. 2017 May 15;8(10):254-256. doi: 10.1213/XAA.0000000000000478.</citation>
    <PMID>28252539</PMID>
  </reference>
  <reference>
    <citation>Ilfeld BM, Madison SJ, Suresh PJ, Sandhu NS, Kormylo NJ, Malhotra N, Loland VJ, Wallace MS, Proudfoot JA, Morgan AC, Wen CH, Wallace AM. Treatment of postmastectomy pain with ambulatory continuous paravertebral nerve blocks: a randomized, triple-masked, placebo-controlled study. Reg Anesth Pain Med. 2014 Mar-Apr;39(2):89-96. doi: 10.1097/AAP.0000000000000035.</citation>
    <PMID>24448512</PMID>
  </reference>
  <reference>
    <citation>Finneran JJ 4th, Gabriel RA, Khatibi B. Erector Spinae Plane Blocks Provide Analgesia for Breast and Axillary Surgery: A Series of 3 Cases. Reg Anesth Pain Med. 2018 Jan;43(1):101-102. doi: 10.1097/AAP.0000000000000695.</citation>
    <PMID>29261601</PMID>
  </reference>
  <reference>
    <citation>Kairaluoma PM, Bachmann MS, Korpinen AK, Rosenberg PH, Pere PJ. Single-injection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with and without associated lymph node biopsy. Anesth Analg. 2004 Dec;99(6):1837-1843. doi: 10.1213/01.ANE.0000136775.15566.87.</citation>
    <PMID>15562083</PMID>
  </reference>
  <reference>
    <citation>Mascha EJ, Turan A. Joint hypothesis testing and gatekeeping procedures for studies with multiple endpoints. Anesth Analg. 2012 Jun;114(6):1304-17. doi: 10.1213/ANE.0b013e3182504435. Epub 2012 May 3.</citation>
    <PMID>22556210</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>July 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Brian M. Ilfeld, MD, MS</investigator_full_name>
    <investigator_title>Professor of Anesthesiology, In Residence</investigator_title>
  </responsible_party>
  <keyword>Regional anesthesia</keyword>
  <keyword>Paravertebral</keyword>
  <keyword>Erector spinae</keyword>
  <keyword>Nerve block</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03549234/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03549234/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erector Spinae (Single Injection)</title>
          <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
        </group>
        <group group_id="P2">
          <title>Paravertebral (Single Injection)</title>
          <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erector Spinae (Single Injection)</title>
          <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
        </group>
        <group group_id="B2">
          <title>Paravertebral (Single Injection)</title>
          <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" lower_limit="48" upper_limit="63.8"/>
                    <measurement group_id="B2" value="54.5" lower_limit="44" upper_limit="67.8"/>
                    <measurement group_id="B3" value="54.5" lower_limit="47" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numeric Rating Scale Pain Scores</title>
        <description>Range scale minimum 0, maximum 10. Lower pain scores are considered a better outcome, higher pain scores are considered a worse outcome.</description>
        <time_frame>1 day (PACU pain scores)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erector Spinae (Single Injection)</title>
            <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
          <group group_id="O2">
            <title>Paravertebral (Single Injection)</title>
            <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Rating Scale Pain Scores</title>
          <description>Range scale minimum 0, maximum 10. Lower pain scores are considered a better outcome, higher pain scores are considered a worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.25" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We hypothesized that 1) analgesia would be noninferior in the recovery room as measured on a Numeric Rating Scale with ESPB (erector spinae plane block), and 2) opioid consumption would be noninferior in the operating and recovery rooms with ESPB. We simulated pain scores from a discrete distribution with median (interquartile range) 2 (0-3). The sample size of 50 per group provided 81% power to detect noninferiority in pain.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>We tested the noninferiority of ESPB compared to PVB (paravertebral block) using the 95% confidence interval (CI) associated with the Wilcoxon-Mann-Whitney Exact test. If the lower limit of the 95% CI for median &quot;average&quot; recovery room pain scores was greater than -1.25 (based on PVB minus ESPB), we concluded noninferiority. The noninferiority of ESPBs with regard to opioid consumption was similarly tested with a predefined noninferiority margin of 2 mg intravenous morphine equivalents.</non_inferiority_desc>
            <p_value>0.0011</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OR and PACU Opioid Consumption</title>
        <description>This outcome measure reflects the total amount of opioid administered in the operating room and recovery room perioperatively. Specific time points are not applicable since operating room and recovery room times differ among subjects.</description>
        <time_frame>up to 1 day, in the OR and PACU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erector Spinae (Single Injection)</title>
            <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
          <group group_id="O2">
            <title>Paravertebral (Single Injection)</title>
            <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
        </group_list>
        <measure>
          <title>OR and PACU Opioid Consumption</title>
          <description>This outcome measure reflects the total amount of opioid administered in the operating room and recovery room perioperatively. Specific time points are not applicable since operating room and recovery room times differ among subjects.</description>
          <units>morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.14" upper_limit="4.52"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.00" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>We tested the noninferiority of ESPB compared to PVB using the 95% confidence interval (CI) associated with the Wilcoxon-Mann-Whitney Exact test. If the lower limit of the 95% CI for median &quot;average&quot; recovery room pain scores was greater than -1.25 (based on PVB minus ESPB), we concluded noninferiority. The noninferiority of ESPBs with regard to opioid consumption was similarly tested with a predefined noninferiority margin of 2 mg intravenous morphine equivalents.</non_inferiority_desc>
            <p_value>0.0043</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Nausea and Vomiting</title>
        <description>Nausea and vomiting was recorded using a 0-10 Likert scale (0 = no nausea; 10 = vomiting) on postoperative day 1. Higher scores represent a worse outcome.</description>
        <time_frame>postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erector Spinae (Single Injection)</title>
            <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
          <group group_id="O2">
            <title>Paravertebral (Single Injection)</title>
            <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea and Vomiting</title>
          <description>Nausea and vomiting was recorded using a 0-10 Likert scale (0 = no nausea; 10 = vomiting) on postoperative day 1. Higher scores represent a worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sleep Disturbances</title>
        <time_frame>postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erector Spinae (Single Injection)</title>
            <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
          <group group_id="O2">
            <title>Paravertebral (Single Injection)</title>
            <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Disturbances</title>
          <units>awakenings</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Block Resolution</title>
        <description>This was recorded as the time at which a participant subjectively noticed that the nerve block was wearing off and sensation was returning.</description>
        <time_frame>postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erector Spinae (Single Injection)</title>
            <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
          <group group_id="O2">
            <title>Paravertebral (Single Injection)</title>
            <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Block Resolution</title>
          <description>This was recorded as the time at which a participant subjectively noticed that the nerve block was wearing off and sensation was returning.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="9.66" upper_limit="20.07"/>
                    <measurement group_id="O2" value="16.0" lower_limit="11.88" upper_limit="19.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Opioid Consumption</title>
        <description>Number of oxycodone tablets (in mg) taken by the participant after discharge from the recovery room was recorded during follow-up on postoperative day 1.</description>
        <time_frame>postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erector Spinae (Single Injection)</title>
            <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
          <group group_id="O2">
            <title>Paravertebral (Single Injection)</title>
            <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Number of oxycodone tablets (in mg) taken by the participant after discharge from the recovery room was recorded during follow-up on postoperative day 1.</description>
          <units>mg oxycodone</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erector Spinae (Single Injection)</title>
          <description>Erector Spinae (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
        </group>
        <group group_id="E2">
          <title>Paravertebral (Single Injection)</title>
          <description>Paravertebral (single injection): Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Swisher, MD</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>415-314-4099</phone>
      <email>matthew.swisher@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

